Condition: B Cell Lymphoma · NHL, Adult · Mantle Cell Lymphoma · Sponsor: Verismo Therapeutics
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
This description comes directly from the study's public registry record.
Physician Connect · 267-392-6847 · physician.connect@verismotherapeutics.com
Always discuss trial participation with your own doctor first.
| Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute | Denver, Colorado, United States | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| The University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06544265